CBIO
Crescent Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.88
+2.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 11.9M | 10.8M | — | 10.0K | 75.0K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 11.9M | 10.8M | — | 10.0K | 75.0K |
| Operating Expenses | |||||
| R&D Expense | 152.7M | 138.1M | 28.1M | 20.1M | 28.4M |
| SG&A Expense | 29.5M | 25.4M | 16.3M | 19.2M | 19.1M |
| General & Admin Expense | 29.5M | 25.4M | 16.3M | 19.2M | 19.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.8M) | — | 5.5M | 637.00 | 443.00 |
| Total Operating Expenses | 180.4M | 163.5M | 49.9M | 39.3M | 47.5M |
| Cost and Expenses | 180.4M | 163.5M | 49.9M | 39.3M | 47.5M |
| Operating Income (EBIT) | (168.5M) | (152.6M) | (49.9M) | (39.3M) | (47.4M) |
| Non-Operating | |||||
| Interest Income | 5.3M | 2.9M | 1.0M | 2.4M | 714.5K |
| Interest Expense | — | 2.2M | 852.0K | — | — |
| Net Interest Income | 5.3M | 690.0K | 149.2K | 2.4M | 714.5K |
| Other Non-Op Income/Expense | 5.3M | 690.0K | 1.4M | 2.4M | 715.0K |
| Non-Operating Income (excl Interest) | (5.3M) | (2.9M) | (5.7M) | (637.00) | (443.00) |
| EBT (Pre-Tax Income) | (163.1M) | (151.9M) | (48.5M) | (36.9M) | (46.7M) |
| Income Tax Expense | 2.0M | 2.0M | — | — | — |
| Bottom Line | |||||
| Net Income | (163.0M) | (153.9M) | (48.5M) | (36.9M) | (46.7M) |
| Earnings from Cont. Ops | (165.1M) | (153.9M) | (48.5M) | (36.9M) | (46.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (163.0M) | (153.9M) | (48.5M) | (36.9M) | (46.7M) |
| Per Share | |||||
| Basic EPS | ($7.58) | ($14.78) | ($63.22) | ($58.25) | ($88.88) |
| Diluted EPS | ($7.58) | ($14.78) | ($63.22) | ($58.25) | ($88.88) |
| Revenue Per Share | $0.39 | $1.04 | $0.00 | $0.02 | $0.14 |
| Shares | |||||
| Basic Shares Outstanding | 30.5M | 10.4M | 767580 | 633424 | 525311 |
| Diluted Shares Outstanding | 30.5M | 10.4M | 767580 | 633424 | 525311 |
| Profitability Metrics | |||||
| EBITDA | (162.9M) | (149.7M) | (44.2M) | (39.1M) | (47.2M) |
| D&A | 212.0K | 84.0K | 35.2K | 153.3K | 207.1K |
| EBIT | (163.1M) | (149.8M) | (44.2M) | (39.3M) | (47.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026